These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia
(HPRL) as a common adverse effect of antipsychotic medication, which remains the …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

Although non‐adherence is common across all branches of medicine, psychotic disorders
pose additional challenges that increase its risk. Despite the importance of non‐adherence …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

In this issue of Structure, Holmes et al.(2005) describe elements of an innate defense
mechanism that provides mammals a means to restrict bacterial growth. The host protein …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

The National Institute of Mental Health convened a meeting in October 2005 to review the
literature on obesity, nutrition, and physical activity among those with mental disorders. The …

Objective: To assess the efficacy and safety of aripiprazole versus placebo as adjunctive
treatment to standard antidepressant therapy (ADT) in patients with major depressive …

This review examines the development of dopamine partial agonists as a new class of
antipsychotic agents. Partial agonists have a lower intrinsic activity at receptors than full …